CD8A and myeloid sarcoma: While an extensive literature has documented the role of Kv1.3 in CD4+ T cell direct effector function in autoimmune diseases, the novel additional inhibitory effects described herein on GrB release from CD8+ effector cells may be especially relevant in MS, as a means of protecting neurons and axons from direct cytoxicity [15], [16].